中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:121 更新时间:2025-03-04
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!通过在本页面挂载中生北控BioSino品牌的产品链接和联系邮箱,可以提高中生北控BioSino产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

银行理财加大权益投资力度,指数化布局渐成趋势

今年以来,多家理财公司均表示将加大权益投资力度,推动中长期资金入市。业界对权益市场的后续表现更加乐观,越来越多的理财公司也通过挂钩特定市场指数,增配权益资产。近期一批挂钩被动指数的银行理财产品进入募集或待售阶段,指数化投资的理财产品数量显著增多。多家理财公司认为,指数型权益理财产品是促进理财资金入市的最好切入点。(证券时报)

26分钟前

华泰证券:价格拐点将至,关注本土存储产业链投资机遇

36氪获悉,华泰证券认为,存储模组环节处于行业下游,伴随行业价格企稳回升,其业绩有望率先迎来拐点。国内存储模组公司产品技术能力日趋完善,横向扩充产品品类,逐步实现从消费类向企业级/车规级产品的拓展,纵向发力主控芯片及封测领域,实现自主供应,提升综合竞争力。存储价格拐点将至,我们看好国内模组产业链相关公司充分受益于行业周期向上,以及国内AI基建加码带动的eSSD等企业级模组需求增长和国产替代加速。

26分钟前

日本1月失业率为2.5%

日本政府3月4日公布数据,1月失业率为2.5%,预期2.4%,去年12月失业率为2.5%。日本失业率数据发布后,日元兑美元维持涨势。(界面)

26分钟前

中金:AI+金融有望迎来规模化拐点

36氪获悉,中金公司研报指出,AI技术平权持续,金融IT行业具备明确赋能场景,有望实现“工具赋能”向“智能重构”跃迁。需求端DeepSeek高性能、低成本特性推升客户采用意愿,供给端金融IT厂商产品升级带来落地商机。DeepSeek等AI工具在核心决策、风控等环节,助力金融科技公司加速探索。在技术可用性、数据完备性与付费确定性三重共振下,AI+金融已迈向全域赋能的新周期,智能化重构带来的产业价值重估机遇亟待关注。

26分钟前

科技股涨到头了吗? 多数私募心态仍偏积极

刚刚过去的2月,DeepSeek刺激中国科技股大幅度上涨,美国科技股则大幅度下跌。2月,A股日均成交量显著放大至1.7万亿元以上,港股日均成交量则跳升至3000亿港元。从申万一级行业的层面来看,计算机和机械设备板块的涨幅均超过10%,排名领先。经过前期快速上涨后,人工智能、人形机器人等热门板块有所回调。不过,多数私募机构心态总体仍然偏向积极,即便是获利减仓也对后市保持乐观判断。(证券时报)

26分钟前

本页详细列出关于赛福基因的品牌信息,含品牌所属公司介绍,赛福基因所处行业的品牌地位及优势。
咨询